In February 2017, PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive BC with Low to Intermediate HER2 Expression with NeuVax Treatment) successfully concluded the evaluation of treatment with NeuVax plus GM-CSF versus placebo plus GM-CSF to prevent cancer recurrence in node positive, HER2 IHC 1+/2+, and HLA-A2+ and/or A3+ patients (ClinicalTrials.gov identifier: NCT01479244). This evidence concerns the gene CSF2 and cancer.